Department of Human Oncology, University of Wisconsin-Madison, USA.
Am J Clin Oncol. 2010 Dec;33(6):646-9. doi: 10.1097/COC.0b013e3181cdf0fe.
Besides photons and electrons, high-energy particles like protons, neutrons, ⁴He ions or heavier ions (C, Ne, etc) have been finding increasing applications in the treatment of radioresistant tumors and tumors located near critical structures. The main difference between photons and hadrons is their different biologic effect and depth-dose distribution. Generally speaking, protons are superior in dosimetric aspects whereas neutrons have advantages in biologic effectiveness because of the high linear energy transfer. In 1946 Robert Wilson first published the physical advantages in dose distribution of ion particles for cancer therapy. Since that time hadronic radiotherapy has been intensively studied in physics laboratories worldwide and clinical application have gradually come to fruition. Hadron therapy was made possible by the advances in accelerator technology, which increases the particles' energy high enough to place them at any depth within the patient's body. As a follow-up to the previous article Introduction to Hadrons, this review discusses certain biologic and dosimetric aspects of using protons, neutrons, and heavy charged particles for radiation therapy.
除了光子和电子,高能粒子如质子、中子、⁴He 离子或更重的离子(C、Ne 等)在治疗耐辐射肿瘤和靠近关键结构的肿瘤方面的应用越来越多。光子和强子之间的主要区别在于它们不同的生物效应和深度剂量分布。一般来说,质子在剂量学方面具有优势,而中子由于高线性能量转移而在生物效应方面具有优势。1946 年,Robert Wilson 首次发表了离子粒子在癌症治疗中的剂量分布的物理优势。从那时起,强子放射治疗在世界各地的物理实验室得到了深入研究,临床应用也逐渐取得了成果。强子治疗是通过加速器技术的进步实现的,该技术将粒子的能量提高到足以将它们放置在患者体内的任何深度。作为上一篇文章《强子简介》的后续,这篇综述讨论了使用质子、中子和重带电粒子进行放射治疗的某些生物学和剂量学方面。